A "breakthrough" Alzheimer's drug now looks much less promising after follow-up experiments failed to reproduce successful results, scientists recently announced. Non-standard use of the drug should be halted, they say.
Alzheimer's researchers met with disappointment Monday when officials from Pfizer announced that the experimental drug bapineuzumab failed to improve dementia symptoms in a Phase 3 trial.
Alzheimer's researchers got a huge boost last week with the publication of a study showing that a rare genetic mutation prevents the buildup of beta amyloid in the brain.
A new test that measures amyloid levels in the spinal fluid of people with mild cognitive impairment could help physicians more accurately predict who will develop Alzheimer's, a new study finds.
Nuclear medicine experts say positron emission tomography (PET) scans that detect beta amyloid plaques in the brain could make it to the marketplace within the next year. Beta-amyloid is a naturally occurring protein that is directly implicated in the development of Alzheimer's.